Kaplan-Meier survival curves for overall survival of MBC by highest tertile of IFN-γ signature vs. the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Study flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan–Meier survival curves for overall survival of NMIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Sample flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for overall survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for progression-free survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Characteristics of bladder cancer patients by stage. by Christina Gillezeau (5348660)

Subjects:

Hazard ratios (HR) and 95% confidence intervals (CI) for the association between INF- γ signature levels and death among bladder cancer patients by stage. by Christina Gillezeau (5348660)

Subjects:

Scatter plot for the absolute decrease in CS rates (A) and the relative decrease in CS rates (B) from 2008 to 2016 among hospitals in Guangzhou grouped by their baseline CS rates. by Xiaoyan Xia (560153)

“…One circle represents one hospital, with blue (<i>n</i> = 20), green (<i>n</i> = 36), orange (<i>n</i> = 34), and purple (<i>n</i> = 22) representing baseline CS rates of <30%, 30%–39%, 40%–49%, and ≥50%, respectively. The absolute decrease = the CS rate at baseline − the CS rate in Stage 2; the relative decrease = (the CS rate at baseline − the CS rate in Stage 2) ÷ the CS rate at baseline. …”

Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

Subjects:

PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

Subjects:

Data extraction grid. by Heloisa Ricci Conesa (18291210)

Subjects:

Introduction status of PCVs in European countries over time. by Heloisa Ricci Conesa (18291210)

Subjects:

Serotype-specific penicillin non-susceptibility during different PCV periods in Iceland, Romania, Spain and Belgium [68, 69, 76, 78, 84, 85]. by Heloisa Ricci Conesa (18291210)

Subjects:

Serotype distributions over time for reported "non-PCV" serotypes. by Heloisa Ricci Conesa (18291210)

Subjects:

Estimates for direct medical and total costs per AOM episode (2020 EUR), by country [35, 96–100]. by Heloisa Ricci Conesa (18291210)

Subjects:

Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

Subjects:

Inclusion criteria. by Heloisa Ricci Conesa (18291210)

Subjects:

Frequency (%) of PCV-serotypes identified between 2011–2021 by testing source and country. by Heloisa Ricci Conesa (18291210)

Subjects:

Penicillin non-susceptibility¹ of S. pneumoniae over time, by country and sample size [11, 12, 60, 66, 68–73, 75–77, 79–86]. by Heloisa Ricci Conesa (18291210)

Subjects: